Enliven Positive Proof of Concept Data from Phase 1 Trial of ELVN-001 in Chronic Myeloid Leukemia

 Achieved initial cumulative MMR rate of 44% (7/16) by 12 weeks in response-evaluable patients, which compares favorably to precedent Phase 1 trials of approved BCR::ABL1 TKIs

Achieved initial cumulative MMR rate of 44% (4/9) by 12 weeks in response-evaluable patients who were previously treated with asciminib

ELVN-001 was well tolerated with no ≥ Grade 3 treatment-related non-hematologic toxicities reported 

Company to host virtual event with Key Opinion Leaders at 8:00 AM ET Today

Enliven is hosting a company event with KOLs today at 8:00 AM ET. The event will feature leading CML investigators and hematology care experts, Michael Mauro, M.D., from Memorial Sloan Kettering Cancer Center, and Fabian Lang, M.D., from Goethe University Hospital, along with the management of Enliven Therapeutics. The discussion will cover details of ELVN-001’s Phase 1 initial proof of concept data, the evolving treatment paradigm in CML, and how ELVN-001 could fit into the CML landscape.

The event will be webcast live and can be accessed by visiting the investor relations section of the Company’s website at https://ir.enliventherapeutics.com. To participate in the live event, please register using this link. An archived webcast will be available following the event.

https://www.globenewswire.com/news-release/2024/04/11/2861409/0/en/Enliven-Therapeutics-Announces-Positive-Proof-of-Concept-Data-from-Phase-1-Clinical-Trial-of-ELVN-001-in-Chronic-Myeloid-Leukemia.html